167 related articles for article (PubMed ID: 24549248)
1. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.
Peters I; Gebauer K; Dubrowinskaja N; Atschekzei F; Kramer MW; Hennenlotter J; Tezval H; Abbas M; Scherer R; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2014 Apr; 31(4):1523-30. PubMed ID: 24549248
[TBL] [Abstract][Full Text] [Related]
2. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
3. Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma.
Peters I; Dubrowinskaja N; Kogosov M; Abbas M; Hennenlotter J; von Klot C; Merseburger AS; Stenzl A; Scherer R; Kuczyk MA; Serth J
BMC Cancer; 2014 Feb; 14():101. PubMed ID: 24533449
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
7. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma.
Gebauer K; Peters I; Dubrowinskaja N; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Br J Cancer; 2013 Jan; 108(1):131-8. PubMed ID: 23321515
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.
Dubrowinskaja N; Gebauer K; Peters I; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Grünwald V; Kuczyk MA; Serth J
Cancer Med; 2014 Apr; 3(2):300-9. PubMed ID: 24464810
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
11. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
[TBL] [Abstract][Full Text] [Related]
12. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.
Zhang X; Song YF; Lu HN; Wang DP; Zhang XS; Huang SL; Sun BL; Huang ZG
World J Gastroenterol; 2015 Mar; 21(9):2629-37. PubMed ID: 25759530
[TBL] [Abstract][Full Text] [Related]
13. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.
Atschekzei F; Hennenlotter J; Jänisch S; Großhennig A; Tränkenschuh W; Waalkes S; Peters I; Dörk T; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Epigenetics; 2012 May; 7(5):447-57. PubMed ID: 22419128
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.
Katzendorn O; Peters I; Dubrowinskaja N; Tezval H; Tabrizi PF; von Klot CA; Hennenlotter J; Lafos M; Kuczyk MA; Serth J
BMC Cancer; 2021 Apr; 21(1):444. PubMed ID: 33882870
[TBL] [Abstract][Full Text] [Related]
15. Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.
Peters I; Dubrowinskaja N; Tezval H; Kramer MW; von Klot CA; Hennenlotter J; Stenzl A; Scherer R; Kuczyk MA; Serth J
Target Oncol; 2015 Jun; 10(2):267-75. PubMed ID: 25230694
[TBL] [Abstract][Full Text] [Related]
16. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma.
Wang D; Yang PN; Chen J; Zhou XY; Liu QJ; Li HJ; Li CL
Mol Cell Biochem; 2014 Nov; 396(1-2):67-77. PubMed ID: 25148870
[TBL] [Abstract][Full Text] [Related]
18. CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.
Carter JA; Górecki DC; Mein CA; Ljungberg B; Hafizi S
Epigenetics; 2013 Jul; 8(7):739-47. PubMed ID: 23803643
[TBL] [Abstract][Full Text] [Related]
19. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
20. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.
Hellebrekers DM; Lentjes MH; van den Bosch SM; Melotte V; Wouters KA; Daenen KL; Smits KM; Akiyama Y; Yuasa Y; Sanduleanu S; Khalid-de Bakker CA; Jonkers D; Weijenberg MP; Louwagie J; van Criekinge W; Carvalho B; Meijer GA; Baylin SB; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2009 Jun; 15(12):3990-7. PubMed ID: 19509152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
